02:49:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaOB Match
IndustriLäkemedel & Handel
Nordic Nanovector är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo.


2021-11-18 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning NANOV 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning NANOV 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning NANOV 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NANOV 0.00 NOK
2018-05-30 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning NANOV 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning NANOV 0.00 NOK
2016-05-19 Kvartalsrapport 2016-Q1
2016-05-19 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014
2021-06-02 07:00:17
Oslo, Norway, 2 June 2021

Reference is made to the minutes from Nordic Nanovector ASA's (the "Company")
(OSE: NANOV) annual general meeting held on 28 April 2021 in Oslo, Norway (the

At the AGM, the shareholders approved the issuance of restricted stock units
("RSUs") to board members who elect to receive all or parts of their
remuneration, for the period from the annual general meeting in 2021 to the
annual general meeting in 2022, in the form of RSUs.

The RSUs are non-transferable and each RSU give the right and obligation to
acquire one share in the Company at a price of NOK 0.20 per share (corresponding
to the nominal value of the shares) subject to satisfaction of the applicable
vesting conditions stated in the RSU agreements.

The board members may elect to either (i) receive 100% of the compensation in
RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii)
receive 2/3 of the compensation in cash and 1/3 in RSUs. The election made by
each board member has been set out in the table below. The number of RSUs to be
granted to the members of the Board of Directors is calculated as the NOK amount
of the RSU opted portion of total minimum compensation to the board member,
divided by the market price for the Nordic Nanovector share. The market price is
calculated as volume weighted average share price 10 trading days prior to the
date of the AGM, i.e. NOK 25.68.

Pursuant to the RSU program, the board members have made the following election
and hold the following number of RSUs and shares following such election:

Name Remuneration Allocation Number of Total number of Total
for between RSUs for RSUs out number of
the period cash and the -standing shares
2021 RSUs period
-22 2021-22
Jan H. NOK 620,000  1/3 RSUs 8,047 24,654 29,046
Egberts [1]
Per NOK 390,000  100% Cash 0 0 0
Samuelsson [2] [3]
Solveig NOK 350,000  100% RSUs 13,629 13,629 0
Hellebust [4]
Karin NOK 370,000  1/3 RSUs 4,802 10,181 571
Meyer [5]
Joanna NOK 370,000 1/3 RSUs 4,802 16,232 13,810
Horobin [6]
Jean NOK 370,000 1/3 RSUs 4,802 16,232 9,022
-Pierre [7]
Rainer NOK 350,000  1/3 RSUs 4,543 15,824 5,904
Boehm [8]

1. NOK 600,000 as chairman of the Board and NOK 20,000 as a member of the audit

2. NOK 330,000 as board member, NOK 40,000 as chair of the compensation
committee and NOK 20,000 as a member of the audit committee.

3. Per Samuelsson is not allowed to hold equity in the company due to his
affiliation with HealthCap and will only receive cash.

4. NOK 330,000 as board member and NOK 20,000 as member of the compensation

5. NOK 330,000 as board member and NOK 40,000 as chair of the audit committee.

6. NOK 330,000 as board member, NOK 20,000 as member of the clinical committee
and NOK 20,000 as member of the compensation committee.

7. NOK 330,000 as board member and NOK 40,000 as chair of the clinical

8. NOK 330 000 as board member and NOK 20,000 as member of the clinical

A total of 40,625 RSUs have thus been allocated following the AGM. The RSUs will
vest on 28 April 2022. For further information about the RSU Program see section
6.3.2 to the Company's financial statements for 2020, included in the Company's
annual report for 2020 on page 95.

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.